Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Cloridrato de propranolol em combinação com sintilimabe e quimioterapia à base de platina para tratamento de câncer avançado de pulmão de células não pequenas (BRIO)

18 de novembro de 2026 atualizado por: Fang Wu, Second Xiangya Hospital of Central South University

Estudo do cloridrato de propranolol em combinação com sintilimabe e quimioterapia à base de platina para tratamento de câncer avançado de pulmão de células não pequenas (BRIO)

This study is a prospective multi-center Phase Ib/II clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta-adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

118

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Hunan
      • Changsha, Hunan, China
        • Ainda não está recrutando
        • Hunan Cancer Hospital
        • Contato:
      • Changsha, Hunan, China
        • Ainda não está recrutando
        • The Third Xiangya Hospital of Central South University
        • Contato:
      • Changsha, Hunan, China, 410011
        • Recrutamento
        • The Second Xiangya Hospital of Central south University
        • Contato:
      • Changsha, Hunan, China, 410011
        • Ainda não está recrutando
        • Xiangya hospital of Central South University
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Sign a written informed consent prior to any research-related procedure

  • Age ≥18 years and ≤ 75 years old

  • ECOG PS score of 0-1

  • Expected survival time ≥ 12 weeks

  • Patients with histologically or cytologically confirmed non-localizable stage IIIB-IIIC, stage IV non-small cell lung cancer (International Association for the Study of Lung Cancer and the Joint Committee on the American Classification of Cancers, 8th edition). Patients with unresectable IIIB-IIIC include recurrent and primary unresectable (surgery and radical concurrent chemoradiotherapy), and stage IV includes primary or recurrent stage IV but without prior systemic therapy for advanced/metastatic disease.

  • Chemotherapy and chemoradiotherapy are permitted as neoadjuvant/adjuvant treatment as long as the treatment is completed at least 12 months prior to the diagnosis of advanced or metastatic disease

  • There must be no EGFR gene-sensitive mutation, ALK gene fusion or ROS1 gene fusion in non-squamous carcinoma

  • At least one imaging measurable lesion according to the criteria for the evaluation of the efficacy of solid tumors (RECIST version 1.1). A lesion located in the field of exposure to previous radiotherapy is considered measurable if progression is confirmed (within 28 days prior to the first treatment)

  • Subjects with brain metastases who are asymptomatic or whose symptoms have stabilized with local treatment are permitted to be enrolled, provided that the subject meets the following criteria:

    1. Have a measurable lesion outside the CNS.
    2. No CNS symptoms or no worsening of symptoms for at least 2 weeks.
  • Meet the following laboratory indicators (within 14 days before the first treatment):

    1. Blood routine examination: absolute neutrophil count ≥ 1.5 x 10^9/L; platelet count ≥ 100 x 10^9/L; hemoglobin level ≥ 9.0 g/dL (no blood transfusion or erythropoietin-dependent administration within 7 days).
    2. Liver function: total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN in the absence of hepatic metastases; ALT or AST ≤ 5 × ULN in the case of patients with hepatic metastases.
    3. Renal function: serum creatinine (Cr) ≤1.5 times ULN or Cr clearance ≥60 mL/min (Cockcroft-Gault formula), and urine routine test results show urine protein (UPRO) <2+ or 24-hour urine protein quantification <1g.
    4. Coagulation: International Normalized Ratio (INR) ≤ 1.5 times ULN or Prothrombin Time (PT) ≤ 1.5 times ULN within 7 days prior to study treatment; if the subject is receiving anticoagulant therapy, as long as the PT is within the range of the anticoagulant drug
  • Heart function: the New York heart association (NYHA) classification < 3;Left ventricular ejection fraction(LVEF)≥ 50%; Baseline ECG showed no PR interval lengthened or atrioventricular block

  • For female subjects of childbearing potential, a negative urine or serum pregnancy test should be obtained within 3 days prior to receiving the first dose of study drug (Day 1 of Cycle 1). If a negative urine pregnancy test result cannot be confirmed, a blood pregnancy test will be requested. Females not of childbearing potential are defined as being at least 1 year postmenopausal or having undergone surgical sterilization or hysterectomy; if conception is at risk, all subjects (male or female) are required to use contraception with an annual failure rate of less than 1% throughout the treatment period up to 120 days after the end-of-treatment administration of study drug (or 180 days after the end-of-study drug administration)

Exclusion Criteria:

  • Concurrent participation in another interventional clinical study or receipt of another investigational drug, unless participating in an observational clinical study

  • Prior exposure to any anti-PD-1 or anti-PD-L1, PD-L2, CD137, CTLA-4 antibody therapy, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways

  • Systemic therapy with proprietary Chinese medicines with anti-tumor indications or immunomodulatory drugs (including thiopeptides, interferons, interleukins, except those used locally for the control of hydrothorax or ascites) within 2 weeks prior to the first dose

  • Current use of oral or intravenous beta-blockers (e.g., atenolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, sotalol, etc.) cannot be safely switched to a non-beta-blocker

  • There are contraindications to the use of beta-blockers:

    1. Hypersensitivity to any of the components of the product.
    2. Bronchial asthma or risk of bronchospasm.
    3. Ketoacidosis and metabolic acidosis.
    4. Severe or symptomatic bradycardia (resting heart rate ≤55bpm), atrioventricular block (degrees II and III), sinus block, sick sinus node syndrome.
    5. Cardiogenic shock
    6. Right heart insufficiency due to pulmonary hypertension.
    7. Congestive heart failure (class III or IV).
    8. Hypotension (systolic blood pressure < 100 mmHg).
    9. Prolonged fasting.
    10. Severe peripheral circulatory failure (e.g., gangrene).
    11. Symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma.
    12. Unstable angina or variant angina.
    13. Patients on rizatriptan benzoate.
    14. Severe chronic obstructive pulmonary disease (COPD)
    15. Uncontrolled type I or type II diabetes mellitus (glycosylated hemoglobin [HbA1C] > 8.5 or fasting blood glucose > 160 mg/dl at screening).
    16. Current use or within the last 2 years of a non-dihydropyridine calcium channel blocker (NDCCB)
  • Hepatic encephalopathy, hepatorenal syndrome or Child-Pugh class B or more severe cirrhosis

  • Tumor-related intestinal obstruction (within 3 months prior to the signing of the informed consent) or history of inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis

  • Completion of palliative radiotherapy within 7 days prior to the first dose of study drug

  • With clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction

  • History of psychotropic substance abuse or addiction

  • Known hypersensitivity to the active ingredients or excipients of the study drug

  • Known history of primary immunodeficiency or undergoing systemic glucocorticoid therapy or any other form of immunosuppressive therapy

  • Use of immunosuppressive drugs, excluding topical glucocorticoids by nasal, inhalational or other routes or physiological doses of systemic glucocorticoids (i.e., no more than 10 mg/day of prednisone or an equivalent dose of other glucocorticoids), or use of hormones for the prevention of contrast sensitization, within 4 weeks prior to the first dose of study treatment

  • Failure to recover adequately from any intervention-induced toxicity and/or complications (≤ grade 1 or baseline, excluding weakness or alopecia) prior to initiation of treatment

  • Receipt of live attenuated influenza vaccine within 4 weeks prior to the first dose of study treatment or planned for the duration of the study (inactivated injectable viral vaccine against seasonal influenza is permitted up to 4 weeks prior to the first dose; however, live attenuated influenza vaccine is not permitted)

  • Major surgery (craniotomy, thoracotomy, or laparotomy) within 4 weeks prior to the first dose of study treatment or anticipation of major surgery during study treatment; laparoscopic exploratory surgery within 2 weeks prior to the first dose of study treatment

  • Known symptomatic CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may be enrolled in the trial if they are clinically stable (no evidence of imaging progression for at least 4 weeks prior to the first dose of the experimental treatment, no evidence of new brain metastases or increase in size of pre-existing brain metastases as confirmed by repeat imaging) and do not require steroid therapy for at least 14 days prior to the first dose of the experimental treatment. This exception does not include carcinomatous meningitis, which should be excluded regardless of whether it is clinically stable.

  • Presence of clinically uncontrolled pleural effusion or ascites (subjects may be recruited who do not require drainage of the effusion or who do not have a significant increase in the effusion after 3 days of cessation of drainage)

  • Patients with bone metastases at risk of paraplegia

  • Known or suspected autoimmune disease or history of such disease within the last 2 years (patients with vitiligo, psoriasis, alopecia areata or Graves' disease not requiring systemic treatment within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type I diabetes mellitus requiring only insulin replacement therapy may be enrolled)

  • Known to have active tuberculosis.

  • A history of allogeneic organ transplants and allogeneic hematopoietic stem cell transplants is known

  • Known history of human immunodeficiency virus (HIV) infection (HIV-positive)

  • Known acute or chronic active hepatitis B virus (HBsAg-positive and HBVDNA viral load ≥200 IU/mL or ≥10^3 copies/mL) or acute or chronic active hepatitis C virus (HCV antibody-positive and HCV RNA-positive)

  • Active syphilis infection requiring treatment

  • Suffer from interstitial lung disease requiring steroid hormone therapy

  • Serious infections that are active or poorly controlled clinically

  • Severe cardiovascular disease (e.g., myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism); angina pectoris requiring treatment; symptomatic peripheral vascular disease; NYHA cardiac class 3 or 4 congestive heart failure; or uncontrolled ≥class 3 hypertension (diastolic blood pressure ≥100 mm Hg or systolic blood pressure ≥160 mm Hg) despite antihypertensive treatment

  • History of other primary malignancies within 5 years, except:

    1. malignancies that have been in complete remission for at least 2 years prior to enrolment and for which no other treatment was required during the study period.
    2. adequately treated non-melanoma skin cancer or malignant nevus with no evidence of disease recurrence.
    3. adequately treated carcinoma in situ without evidence of disease recurrence
  • Female patients who are pregnant or breastfeeding

  • Other acute or chronic medical conditions, psychiatric disorders, or abnormal laboratory test values that may result in increased risk associated with study participation or administration of study medication, or interfere with the interpretation of study results, and that, in the investigator's judgement, classify the patient as ineligible for participation in this study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: BRIO-I: Phase Ib Dose-Escalation Cohort

Patients receive propranolol hydrochloride PO, sintilimab IV over 30 minutes of day 1 and chemotherapy IV. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

Dose-escalation: 10 mg PO BID, 10 mg PO TID, and 20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Outros nomes:
  • Inderal

intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Platinum-based chemotherapy:

For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4/6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Experimental: BRIO-II: Propranolol Group

In the phase II stage, participants are randomly assigned in a 1:1 ratio to receive propranolol hydrochloride at the recommended phase II dose (RP2D) established during the phase Ib stage, in combination with sintilimab and platinum-based doublet chemotherapy.

intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Platinum-based chemotherapy:

For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4/6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Comparador de Placebo: BRIO-II: Standard Control Group

In the phase II stage, participants are randomly assigned in a 1:1 ratio to receive propranolol hydrochloride matching placebo in combination with sintilimab and platinum-based doublet chemotherapy.

intravenous infusion (IV), 200 mg, Day1, Q3W, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

Platinum-based chemotherapy:

For non-squamous cell carcinoma options: carboplatin/cisplatin + pemetrexed; For squamous cell carcinoma: carboplatin/cisplatin + paclitaxel/gemcitabine. Carboplatin: IV, AUC 5, Day1, Q3W; Cisplatin: IV, 75 mg/m2, Day1, Q3W; Pemetrexed: IV, 500 mg/m2, Day1, Q3W; Paclitaxel: IV, 175 mg/m², Day1, Q3W; Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W; Gemcitabine: IV, 1000mg/m2, Day1, 8, Q3W; After 4/6 cycles of sintilimab and platinum-based chemotherapy, the patients of non-squamous cell carcinoma will be received with sintilimab and pemetrexed for maintenance therapy, for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

20 mg PO BID for up to 2 years until disease progression/intolerable toxicity/withdrawal of informed consent.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Adverse events (AEs) (BRIO-I)
Prazo: 2 years

AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who experienced an AE is presented.

2 years
Recommended phase II dose (RP2D) (BRIO-I)
Prazo: 2 years

The recommended phase II dose (RP2D) of propranolol hydrochloride will be determined based on the incidence of DLTs across dose levels, overall safety and tolerability

2 years
Objective Response Rate (ORR) (BRIO-I)
Prazo: 2 years

The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

2 years
Progression-free survival (PFS) (BRIO-II)
Prazo: 2 years

Time from the randomization to the disease progression (PD) or death, whichever occurs first

2 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall survival (OS)
Prazo: 5 years

Time from the beginning of intervention or randomization until death due to any cause. OS will be evaluated separately for the phase Ib and phase II cohorts.

5 years
Adverse events (AEs) (BRIO-II)
Prazo: 2 years

AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who experienced an AE is presented.

2 years
Quality of life (QoL)
Prazo: 2 years

Health-related quality of life will be assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The questionnaire includes global health status/quality-of-life, functional, and symptom scales, each transformed to a score ranging from 0 to 100. Higher scores indicate better quality of life or functioning on the global health and functional scales, whereas higher symptom scores indicate greater symptom burden.

2 years
Objective Response Rate (ORR) (BRIO-II)
Prazo: 2 years

The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

2 years
Disease Control Rate (DCR)
Prazo: 2 years

Disease Control Rate (DCR) The proportion of patients with a complete response or partial response or stable disease to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). DCR will be evaluated separately for the phase Ib and phase II cohorts.

2 years
Duration of Response (DOR)
Prazo: 2 years

DOR is defined as the time from the first documented complete response or partial response, to disease progression or death from any cause, whichever occurs first. DOR will be evaluated separately for the phase Ib and phase II cohorts.

2 years
Patient-Reported Emotional Distress
Prazo: 2 years

Patient-reported emotional distress will be assessed using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety symptom. Each item is rated on a 4-point Likert scale: 0 (not at all), 1 (several days), 2 (more than half the days), or 3 (nearly every day). The total scores range from 0 to 27 for the PHQ-9 and from 0 to 21 for the GAD-7, with higher scores indicating greater symptom severity. Emotional distress is defined as PHQ-9 scores ≥5 and/or GAD-7 scores ≥5.

2 years
Patient-Reported Dispositional Optimism
Prazo: 2 years

The dispositional optimism is evaluated by Life Orientation Test-Revised (LOT-R), Each item is rated on a 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree). LOT-R consists of 3 positively worded items and 3 negatively worded items, with a total score ranging from 0 to 24. Higher scores indicate greater dispositional optimism.

2 years
Patient-Reported Psychological Well-Being
Prazo: 2 years

Psychological well-being will be assessed using the World Health Organization-Five Well-Being Index (WHO-5). The questionnaire consists of five items, each rated on a 6-point Likert scale ranging from 0 (at no time) to 5 (all of the time). The total raw score ranges from 0 to 25 and is multiplied by four to yield a standardized score ranging from 0 to 100. Higher scores indicate better psychological well-being.

2 years
Patient-Reported Sleep Quality
Prazo: 2 years

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI) for sleep quality, Insomnia Severity Index (ISI) for insomnia severity. PSQI comprises seven components, each scored from 0 to 3. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 28. Higher scores indicate greater insomnia severity. poor sleep quality is defined as a PSQI score ≥5 and/or an ISI score ≥8.

2 years
Patient-Reported Perceived Stress
Prazo: 2 years

The perceived stress level is evaluated by the 10-item Perceived Stress Scale (PSS-10). Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often), with a total score ranging from 0 to 40. The PSS-10 consists of six positively worded items and four negatively worded items. Higher scores indicate greater perceived stress.

2 years
Patient-Reported Sleep Circadian preference
Prazo: 2 years

Circadian preference will be assessed using the 5-item reduced Morningness-Eveningness Questionnaire (rMEQ). The total score ranges from 4 to 25, with higher scores indicating a stronger morningness preference.

2 years
Progression-free survival (PFS) (BRIO-I)
Prazo: 2 years

Time from the beginning of intervention to the first disease progression (PD)

2 years

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Exploratory Peripheral Blood Biomarkers
Prazo: 2 years

Exploratory analyses will investigate potential associations between clinical outcomes and biomarkers derived from peripheral blood. These analyses may include circulating stress-related hormones, immune cell profiles, molecular and metabolic biomarkers.

2 years
Exploratory Biomarkers in Tumor Microenvironment
Prazo: 2 years

Exploratory analyses will investigate potential associations between clinical outcomes and biomarkers derived from tumor tissue. These analyses may include immune cell profiles, molecular and metabolic biomarkers.

2 years
Exploratory Biomarkers in Gut microbiota
Prazo: 2 years

Exploratory analyses will investigate potential associations between clinical outcomes and biomarkers derived from stool samples. These analyses may include gut microbiota related composition.

2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

13 de novembro de 2024

Conclusão Primária (Estimado)

31 de outubro de 2028

Conclusão do estudo (Estimado)

31 de dezembro de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

31 de julho de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

31 de julho de 2023

Primeira postagem (Real)

7 de agosto de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

18 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever